All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Sequencing of targeted therapies in relapsed follicular lymphoma
Bookmark this article
During ASCO 2019 held in Chicago, US, Anna M Sureda, Catalan Institute of Oncology, Barcelona, ES, spoke to the Lymphoma Hub about the sequencing of targeted therapies in patients with relapsed follicular lymphoma.
Dr. Sureda explains how most patients are not being cured with first-line chemotherapy and in daily clinical practice, physicians are faced with many difficult patients, that need additional treatment. Dr. Sureda explains that there are several types of targeted therapies that have given interesting results most of which are in phase II prospective clinical trials and some even in phase III prospective trials that have been able to improve the long term outcomes of patients, these include new anti-CD20 monoclonal antibodies, PA3K inhibitors, and antibody drug conjugates.
Sequencing of targeted therapies in relapsed follicular lymphoma
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox